These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 10806004

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ.
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract] [Full Text] [Related]

  • 3. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.
    N Engl J Med; 1999 Jul 29; 341(5):319-27. PubMed ID: 10423466
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A.
    Med Monatsschr Pharm; 2000 Dec 29; 23(12):385-90. PubMed ID: 11147193
    [No Abstract] [Full Text] [Related]

  • 6. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
    Internist (Berl); 1998 Dec 29; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692
    [No Abstract] [Full Text] [Related]

  • 7. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Rossi ML, Merlini PA.
    Ital Heart J Suppl; 2001 Oct 29; 2(10):1130-2. PubMed ID: 11723620
    [No Abstract] [Full Text] [Related]

  • 8. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials.
    van de Werf F.
    Eur Heart J; 1996 Mar 29; 17(3):325-6. PubMed ID: 8737200
    [No Abstract] [Full Text] [Related]

  • 9. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS, Mukhopadhyay S.
    Indian Heart J; 2000 Mar 29; 52(5):524-32. PubMed ID: 11256774
    [No Abstract] [Full Text] [Related]

  • 10. Care of the patient receiving ReoPro following angioplasty.
    Brezina K, Murphy M, Stonner T.
    J Invasive Cardiol; 1994 Mar 29; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines.
    Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA.
    J Am Coll Cardiol; 2011 Mar 08; 57(10):1190-9. PubMed ID: 21371635
    [Abstract] [Full Text] [Related]

  • 12. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D, Roffi M.
    J Interv Cardiol; 2008 Apr 08; 21(2):118-21. PubMed ID: 18384343
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L, TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.
    N Engl J Med; 2001 Jun 21; 344(25):1888-94. PubMed ID: 11419425
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Optimization of platelet therapy.
    Fry JA, Grines CL.
    Semin Interv Cardiol; 2000 Sep 21; 5(3):117-28. PubMed ID: 11054909
    [Abstract] [Full Text] [Related]

  • 16. Platelet glycoprotein IIb/IIIa receptor blockade after coronary angioplasty.
    Gambassi G, Landolfi R, Bernabei R.
    N Engl J Med; 1997 Oct 23; 337(17):1243-4. PubMed ID: 9340528
    [No Abstract] [Full Text] [Related]

  • 17. Use of abciximab in interventional cardiology.
    Chronos N, Vahanian A, Betriu A, Emanuelsson H, Goldberg S, Gulba D, van Hout BA.
    Eur Heart J; 1998 Apr 23; 19 Suppl D():D31-9. PubMed ID: 9597520
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan 23; 63(1):8-15. PubMed ID: 10645045
    [Abstract] [Full Text] [Related]

  • 19. The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty.
    Fischman DL, Savage MP.
    JAMA; 1997 Aug 13; 278(6):518-9. PubMed ID: 9256229
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.